Title |
-
en
Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer
|
Creator |
|
Accessrights |
open access |
Rights |
-
en
The final publication is available at link.springer.com
|
Subject |
-
Other
en
Breast cancer
-
Other
en
Neoadjuvant chemotherapy
-
Other
en
Pathologic complete response
-
Other
en
Ki67
-
NDC
490
|
Description |
-
Abstract
en
Recent studies have indicated that response to chemotherapy and the prognostic impact of a pathologic complete response (pCR) after neoadjuvant chemotherapy differ among breast cancer subtypes. Women with Stage I to III breast cancer treated with anthracycline and taxane-based neoadjuvant chemotherapy (four cycles of docetaxel every 3 weeks followed by four cycles of FEC every 3 weeks) between 2006 and 2011 were retrospectively analyzed. Trastuzumab was concurrently added to docetaxel for HER2-positive breast cancer. Expression of estrogen receptor (ER), progesterone receptor (PgR), HER2, and Ki67 was examined by immunohistochemistry in pre- and post-treatment specimens. Predictive factors for neoadjuvant chemotherapy and prognosis were analyzed by breast cancer subtype. Of 64 patients, 30 (47 %) were ER-positive (ER+) HER2-negative (HER2-), including eight as luminal A (Ki67 labeling index (LI) < 14 %) and 22 as luminal B (Ki67 LI a parts per thousand yen 14 %) subtypes, 11 (17 %) were ER+ HER2-positive (HER2+), 12 (19 %) were ER-negative (ER-) HER2+, and 11 (17 %) were ER- HER2-. The clinical response rates were significantly higher in luminal B, ER+ HER2+, and ER- HER2+ subtypes compared with luminal A subtype. Patients whose tumors contained high Ki67 expression effectively responded to neoadjuvant chemotherapy. Ki67 LI was a predictive marker for pCR, and all patients whose tumors achieved pCR are currently disease-free. Furthermore, high Ki67 expression in post-treatment tumors was strongly correlated with poor disease-free and overall survival regardless of subtype. It is necessary to establish additional strategies to improve survival for patients whose residual tumors show high Ki67 expression after neoadjuvant chemotherapy.
|
Publisher |
en
Springer Japan Kk
|
Date |
|
Language |
|
Resource Type |
journal article |
Version Type |
AM |
Identifier |
HDL
http://hdl.handle.net/2115/60736
|
Relation |
-
isVersionOf
DOI
https://doi.org/10.1007/s12282-013-0474-2
-
PMID
23645542
|
Journal |
-
-
en
Breast Cancer
-
Volume Number22
Issue Number2
Page Start185
Page End191
|
File |
-
-
fulltext
Paper.pdf
-
800.76 KB
(application/pdf)
-
|
Oaidate |
2023-07-26 |